News

Celgene Corporation announced the U.S. Food and Drug Administration (FDA) approved REVLIMID (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult…
Read More...

Pfizer Inc. announced that a Phase 3 study to assess the use of LYRICA (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized…
Read More...

AveXis, a Novartis company, announced innovative access programs for Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than 2 years of age with…
Read More...

Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi (ruxolitinib) for the treatment of steroid-refractory acute GVHD in adult and pediatric…
Read More...

Pfizer Inc. announced that a Phase 3 study to assess the use of LYRICA (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized…
Read More...

AveXis, a Novartis company, announced the US Food and Drug Administration (FDA) has approved Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than…
Read More...

GlaxoSmithKline plc announced that the National Medical Products Administration (NMPA) has approved Shingrix for the prevention of shingles (herpes zoster) in adults aged 50 years or…
Read More...

ProBioGen AG announced the closing of a services and license agreement with Abcuro, Inc. Pursuing a new generation of immune modulatory bio-therapeutics, Abcuro has developed a new…
Read More...

Santhera Pharmaceuticals announces that it has entered into an exclusive license agreement with Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group),…
Read More...

Trovagene, Inc., a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of…
Read More...

CALECIM Cosmeceuticals (CALECIM), a wholly owned subsidiary of biotechnology company CellResearch Corporation (CRC), has formed a major partnership with A. Menarini Asia-Pacific…
Read More...

Aequus Pharmaceuticals Inc. is pleased to announce an agreement for the Zepto Precision Pulse Capsulotomy device with The Kensington Eye Institute, a world renowned clinic and leader in…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental New Drug…
Read More...

Halozyme Therapeutics announced that argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019. The second target…
Read More...

Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and ZoBio, the leading contract research organization in integrated…
Read More...

Merck, known as MSD outside the United States and Canada, and Peloton Therapeutics, Inc. announced that the companies have entered into a definitive agreement under which Merck, through…
Read More...

SGS celebrated the official opening of the Biologics, Viral Vaccine, Gene and Cell Therapy Testing facility expansion in Glasgow, UK earlier this month (Thursday May 9, 2019). The…
Read More...

In an oral presentation from the Digestive Disease Week medical conference in San Diego, California today, Eli Lilly and Company announced new safety and efficacy data for mirikizumab…
Read More...

WuXi Biologics announced that it has entered into a strategic partnership Letter of Intent (LOI) with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated…
Read More...

Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with the Alliance for Clinical Trials…
Read More...